Trials / Active Not Recruiting
Active Not RecruitingNCT04572295
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
An Open-label Phase 1b Study of E7090 Monotherapy and in Combination With Other Anticancer Agents in Subjects With ER+, HER2- Recurrent/Metastatic Breast Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 51 (estimated)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the tolerability and safety of E7090 as monotherapy and in combination with other anticancer agents in participants with ER+, HER2- recurrent/metastatic breast cancer and to determine the recommended dose (RD) of E7090 in combination with other anticancer agents for subsequent phase studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7090 | E7090 oral tablet. |
| DRUG | Fulvestrant | Fulvestrant intramuscular injection. |
| DRUG | Exemestane | Exemestane oral tablet. |
Timeline
- Start date
- 2020-10-09
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
- First posted
- 2020-10-01
- Last updated
- 2026-03-11
Locations
11 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04572295. Inclusion in this directory is not an endorsement.